



iCo Therapeutics Inc (TSX-V: 'ICO')

760-777 Hornby St.
Vancouver, BC

Tel: 604-602-9414
Fax: 604-602-9699

iCo-007: Second Generation Antisense for the Treatment of Diabetic Macular Edema

Worldwide exclusive rights licensed from ISIS Pharmaceuticals (Nasdaq: ISIS)

- ISIS is iCo's largest shareholder (approx. 14%)
- iCo holds rights to all therapeutic indications with a non-compete on target
- Back-ended milestones

Diabetic Macular Edema (DME) Market

- DME is diabetes-related blindness – 22% of all diabetics will experience some form of visual impairment.
- There are no approved therapeutics for Diabetic Macular Edema (DME)
- > 1.6M patients in the US alone
- Diabetes is an explosive problem in the US
- Multi-billion\$ market opportunity
- Limited competitive landscape
- Recent deal for a DME product that had just completed Phase I:
 - **\$50M** upfront for Asian rights. (Santen-MacuSight)

Differentiated product profile

- Long duration in eye means less frequent injection
- injection is the current standard of care in retinal disease management
- Multi-factor approach “VEGF+”
 - Existing competition target VEGF alone
- 2nd generation antisense
 - Potent, specific, and stable
 - iCo's partner, ISIS, holds the predominant patent estate in antisense

Clinical Trial

- Single injection in Diffuse DME patients
- 4 cohorts (110, 350, 700 or 1000 µg), total number of patients = 15
- Open-label, dose escalation study

Primary outcomes

- Safety and tolerability of a single injection of iCo-007

Secondary outcomes

- Visual acuity
- Retinal thickness (OCT)
- Assessment of systemic pharmacokinetic profile

Early results:

- iCo-007 is durable in the eye, (due to long half-life), a key product differentiator.
- Patient dosing is complete and to date, there have been no adverse events of concern.
- While low patient numbers mean the results are not statistically significant, early results in some patients show a decrease in retinal thickness, an important indicator in DME.

Scientific Background

- DME is characterized by new blood vessel growth and increased vascular permeability.
- Drug products that prevent the growth of new blood vessels and inhibit increased vascular permeability may have the potential to treat neovascular diseases, including DME.
- Multiple growth factors are implicated in the etiology of DME and diabetic retinopathy in addition to VEGF.
- iCo-007 inhibits c-Raf expression & blocks MAP kinase signaling

Key Opinion Leaders & Investigators

iCo is associated with a world-class group of retinal specialists and investigators:

Alan C. Bird, M.D. **Moorfields Eye Hospital**

David S. Boyer, M.D. **Retina-Vitreous Associates Medical Group**

Philip Rosenfeld, M.D., PhD. & Geeta Lalwani, M.D., **Bascom Palmer Eye Institute**

Jason Slakter, M.D. **Vitreous-Retina-Macula Consultants of NY**

Karl Csaky, M.D., PhD. **Duke University**

Scott Cousins, M.D. **Duke University**

Victor Gonzales, M.D., **Valley Retina Institute**